Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Myasthenia Gravis Treatment

Published by Global Industry Analysts, Inc. Product code 993392
Published Content info 271 Pages
Delivery time: 1-2 business days
Price
Back to Top
Myasthenia Gravis Treatment
Published: April 1, 2021 Content info: 271 Pages
Description

Abstract:

Global Myasthenia Gravis Treatment Market to Reach $2 Billion by 2027

Amid the COVID-19 crisis, the global market for Myasthenia Gravis Treatment estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$2 Billion by 2027, growing at a CAGR of 6.3% over the analysis period 2020-2027. Medication, one of the segments analyzed in the report, is projected to record a 6.6% CAGR and reach US$1.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Surgery segment is readjusted to a revised 4.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $352 Million, While China is Forecast to Grow at 9.7% CAGR

The Myasthenia Gravis Treatment market in the U.S. is estimated at US$352 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$430 Million by the year 2027 trailing a CAGR of 9.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.4% and 5.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4% CAGR.

Other Treatment Types Segment to Record 3.3% CAGR

In the global Other Treatment Types segment, USA, Canada, Japan, China and Europe will drive the 2.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$47.6 Million in the year 2020 will reach a projected size of US$58.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$270.2 Million by the year 2027, while Latin America will expand at a 4.2% CAGR through the analysis period.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • Alexion Pharmaceutical Inc.
  • Avadel Pharmaceuticals plc
  • Bausch Health Companies Inc.
  • Baxter International, Inc.
  • CSL Behring
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Grifols SA
  • Novartis AG
  • Pfizer, Inc.
  • Shire plc
  • Takeda Pharmaceutical Company Limited
  • Valeant Pharmaceuticals International, Inc.
Table of Contents
Product Code: MCP22340

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Myasthenia Gravis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Myasthenia Gravis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Myasthenia Gravis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Medication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 22: USA Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 23: USA Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: USA 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 25: USA Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 26: USA Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: USA 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 28: Canada Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Canada Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: Canada 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 31: Canada Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Canada Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: Canada 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 34: Japan Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Japan Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: Japan 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 37: Japan Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Japan Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: Japan 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 40: China Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: China Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: China 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 43: China Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: China Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: China 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 46: Europe Current & Future Analysis for Myasthenia Gravis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 47: Europe Historic Review for Myasthenia Gravis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Europe 15-Year Perspective for Myasthenia Gravis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 49: Europe Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Europe Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Europe 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 52: Europe Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Europe Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: Europe 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 55: France Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: France Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: France 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 58: France Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: France Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: France 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 61: Germany Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Germany Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: Germany 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 64: Germany Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Germany Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: Germany 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 67: Italy Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Italy Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: Italy 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 70: Italy Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Italy Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: Italy 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 73: UK Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: UK Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: UK 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 76: UK Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: UK Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: UK 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 79: Spain Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Spain Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: Spain 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 82: Spain Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Spain Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: Spain 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 85: Russia Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Russia Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Russia 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 88: Russia Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Russia Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Russia 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 91: Rest of Europe Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Rest of Europe Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Rest of Europe 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 94: Rest of Europe Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Rest of Europe Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: Rest of Europe 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 97: Asia-Pacific Current & Future Analysis for Myasthenia Gravis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 98: Asia-Pacific Historic Review for Myasthenia Gravis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: Asia-Pacific 15-Year Perspective for Myasthenia Gravis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 100: Asia-Pacific Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Asia-Pacific Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Asia-Pacific 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 103: Asia-Pacific Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Asia-Pacific Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: Asia-Pacific 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 106: Australia Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Australia Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: Australia 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 109: Australia Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Australia Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: Australia 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 112: India Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: India Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: India 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 115: India Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: India Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: India 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 118: South Korea Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: South Korea Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 120: South Korea 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 121: South Korea Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: South Korea Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 123: South Korea 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 124: Rest of Asia-Pacific Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Rest of Asia-Pacific Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 126: Rest of Asia-Pacific 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 127: Rest of Asia-Pacific Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Rest of Asia-Pacific Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 129: Rest of Asia-Pacific 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 130: Latin America Current & Future Analysis for Myasthenia Gravis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 131: Latin America Historic Review for Myasthenia Gravis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 132: Latin America 15-Year Perspective for Myasthenia Gravis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 133: Latin America Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Latin America Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 135: Latin America 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 136: Latin America Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Latin America Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 138: Latin America 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 139: Argentina Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Argentina Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 141: Argentina 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 142: Argentina Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Argentina Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 144: Argentina 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 145: Brazil Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Brazil Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 147: Brazil 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 148: Brazil Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Brazil Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 150: Brazil 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 151: Mexico Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Mexico Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 153: Mexico 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 154: Mexico Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Mexico Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 156: Mexico 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 157: Rest of Latin America Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Rest of Latin America Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 159: Rest of Latin America 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 160: Rest of Latin America Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Rest of Latin America Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 162: Rest of Latin America 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 163: Middle East Current & Future Analysis for Myasthenia Gravis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 164: Middle East Historic Review for Myasthenia Gravis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 165: Middle East 15-Year Perspective for Myasthenia Gravis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 166: Middle East Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Middle East Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 168: Middle East 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 169: Middle East Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Middle East Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 171: Middle East 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 172: Iran Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Iran Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 174: Iran 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 175: Iran Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Iran Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 177: Iran 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 178: Israel Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Israel Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 180: Israel 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 181: Israel Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Israel Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 183: Israel 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 184: Saudi Arabia Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Saudi Arabia Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 186: Saudi Arabia 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 187: Saudi Arabia Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Saudi Arabia Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 189: Saudi Arabia 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 190: UAE Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 191: UAE Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 192: UAE 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 193: UAE Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 194: UAE Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 195: UAE 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 196: Rest of Middle East Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Rest of Middle East Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 198: Rest of Middle East 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 199: Rest of Middle East Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Rest of Middle East Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 201: Rest of Middle East 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 202: Africa Current & Future Analysis for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Africa Historic Review for Myasthenia Gravis Treatment by Treatment Type - Medication, Surgery and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 204: Africa 15-Year Perspective for Myasthenia Gravis Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medication, Surgery and Other Treatment Types for the Years 2012, 2020 & 2027
    • TABLE 205: Africa Current & Future Analysis for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Africa Historic Review for Myasthenia Gravis Treatment by End-Use - Hospitals, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 207: Africa 15-Year Perspective for Myasthenia Gravis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Other End-Uses for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 34
Back to Top